Jade Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
JBIO$16.40+5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(In thousands)
| Three Months EndedMarch 31, 2026 | Three Months EndedMarch 31, 2025 | |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(40,368) | $(38,169) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Change in fair value of Convertible Notes payable | — | 15,400 |
| Stock-based compensation | 7,405 | 2,423 |
| Non-cash lease expense | 26 | 8 |
| Accretion/amortization on investments | (493) | — |
| Depreciation expense | 9 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 5,444 | (507) |
| Other assets | — | (60) |
| Accounts payable | 2,328 | 2,677 |
| Accrued expenses and other current liabilities | 5,772 | (1,948) |
| Related party accrued expenses and other current liabilities | (4,175) | 1,410 |
| Operating lease liabilities | (29) | 9 |
| Net cash used in operating activities | (24,081) | (18,757) |
| Cash flows from investing activities: | ||
| Purchases of investments | (73,898) | — |
| Proceeds from sales/maturities of investments | 65,428 | — |
| Net cash used in investing activities | $(8,470) | $— |
| Cash flows from financing activities: | ||
| Payment of deferred offering costs | — | (700) |
| Issuance costs from the December PIPE Financing | (809) | — |
| Issuance costs from the October PIPE Financing | (31) | — |
| Proceeds from stock option exercises | 45 | — |
| Net cash used in financing activities | (795) | (700) |
| Effect on exchange rates on cash and cash equivalents | (7) | — |
| Net decrease in cash and cash equivalents | (33,353) | (19,457) |
| Cash and cash equivalents at beginning of period | 88,438 | 69,386 |
| Cash and cash equivalents at end of period | $55,085 | $49,929 |
| Supplemental disclosure of non-cash operating, investing, and financing activities: | ||
| Purchases of property and equipment in accounts payable | $— | $5 |
| Deferred offering costs in accounts payable or accrued expenses and other current liabilities | $— | $1,091 |
| Operating lease liability arising from obtaining right-of-use asset | $— | $773 |
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.